Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations

    NEXT STORY
    NILE Study Results Demonstrating Guardant360’s High Concordance to Tissue Testing in Advanced NSCLC Published in Clinical Cancer Research
    PREV STORY
    Sprint Through Real-Time Promo Review
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments

    author_avatar
    NASDAQ Market News

    Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders

    author_avatar
    NASDAQ Market News

    Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting

    Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in ...

    author_avatar
    NASDAQ Market News